Newly Formed Glaucoma Co. Aerie Pharmaceuticals Inks $21M Series A

October 12, 2005 — VetnureWire Alert

Formed around the in-licensing of technology for the treatment of glaucoma from Duke University Medical Center, Aerie Pharmaceuticals has secured $21 million of Series A funding from co-lead investors Alta Partners and TPG Ventures. . [ more... ]

»To read the full story, you'll need to
subscribe to VetnureWire Alert